Dr. Dan Lender, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 74
Licensed in Texas since 1992, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TX license J1293 (first issued 1992; active) · MD license D38003
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Carlos Arauz PAcheco MD PA (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 74
- Services billed
- 193
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 251 | 167 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 120 | 67 |
| Established patient office or other outpatient visit, 20-29 minutes | 38 | 37 |
| Ultrasound scan of head and neck soft tissue | 23 | 23 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | 16 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | 15 | 11 |
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
| Established patient office or other outpatient visit, 40-54 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Rockwall, TX | 91 |
| Rosuvastatin Calcium Other prescribers in Rockwall, TX | 81 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Rockwall, TX | 76 |
| Glimepiride Other prescribers in Rockwall, TX | 71 |
| Metformin Hcl Other prescribers in Rockwall, TX | 71 |
| Trulicity (dulaglutide) Other prescribers in Rockwall, TX | 66 |
| Humalog Kwikpen U-100 (insulin lispro) Other prescribers in Rockwall, TX | 50 |
| Pioglitazone Hcl Other prescribers in Rockwall, TX | 47 |
| Ozempic (semaglutide) Other prescribers in Rockwall, TX | 45 |
| Atorvastatin Calcium Other prescribers in Rockwall, TX | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $27.51 in total to this clinician.
| Abbott Laboratories | $17.59 |
|---|---|
| Beta Bionics, Inc. | $9.92 |
| Food and Beverage | $27.51 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 10 companies. The companies reported $1,396,584 in research payments for these studies, mostly to the institutions running them.
- A master protocol to investigate the efficacy and safety of orforglipron tablet once daily compared with placebo in participants with obesity or overweight with and without type 2 diabetes: J2A-mc-GZP1, J2A-mc-GZP2
Eli Lilly and Company - CT-388-104 OW/OB with T2D
Genentech, Inc. - A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Active, not recruiting · NCT05869903 - Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Eli Lilly and Company · Completed · NCT06354660 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - CT-388-104 OW/OB with T2D
F. Hoffmann-la Roche AG - Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM
Hoffmann-la Roche Limited - Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity
Hoffmann-la Roche Limited - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.